09 November 2020 |

Consolidated financial report as at 30th September 2020

PharmaNutra S.p.A. communicates that the Board of Directors has examined and approved the consolidated financial report as at 30th September 2020, drafted to be included into the Information Prospectus being prepared and related to the listing transaction for the  Pharmanutra S.p.A. shares on the Mercato Telematico Azionario (MTA) – STAR segment being decided, and in compliance with IFRS international accounting standards.

The consolidated report of the PharmaNutra Group dated 30/09/2020 highlights the following figures:

€40.7 m revenue from sales (+11% compared to 30/09/2019)
€12.3 m EBITDA Restated* (+35% compared to 30/09/2019)
€8.9 m net income for the period net of the non-recurring item**(+53% compared to 30/09/2019)
Positive net financial position of €14.1 m

The turnover growth trend shows no sign of stopping, thanks to the increase in sales volumes in Italy and consolidation of the Group’s presence on foreign markets. Period figures confirm the Group’s commercial and financial solidity, a clear sign that the PharmaNutra Group is ready for its move to the STAR market.

Andrea Lacorte, President of PharmaNutra S.p.A., commented:Results achieved are consistent with the growth recorded in the previous months and very positive despite the complex global socio-economic situation caused by the Covid-19 pandemic. PharmaNutra figures and trends confirm their growth thanks to both a solid commercial strategy and continual investments in research and development, which have enabled the Group to position itself in the top 12 nutraceutical companies in Italy and consolidate its reputation with the medical class and consumers. All guaranteed by a very solid financial structure which, along with market results, enables us to look to the future positively”.

Roberto Lacorte, Vice President of PharmaNutra S.p.A., added: “These results strengthen the Group’s long-term strategic growth prospects. We can undoubtedly confidently continue to implement our growth plan: to consolidate the national distribution network, develop new products and expand foreign reference markets. Period figures confirm the Group’s commercial and financial solidity. It has all it takes for an imminent step towards the STAR segment of the MTA market”.

The consolidated financial report as at 30th September 2020, together with the audit report, will be made available to the public on the PharmaNutra S.p.A. website in the “Investor Relations” section.

Click here to read the complete Press Release and the Group accounting prospectus.